Showing Results for
- Academic Journals (40)
Search Results
- 40
Academic Journals
- 40
- Search Terms:
- 1From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedPhosphorylation of the Ser-139 residue of the histone variant H2AX, forming [gamma]H2AX, is an early cellular response to the induction of DNA double-strand breaks. Detection of this phosphorylation event has emerged as...
- 2From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedDasatinib is a potent dual Abl/Src inhibitor approved for treatment of Philadelphia chromosome-positive (Ph-positive) leukemias. At a once-daily dose and a relatively short half-life of 3-5 h, tyrosine kinase inhibition...
- 3From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedAcute lymphoblastic leukemia (ALL) harboring the t(4;11) translocation is associated with a very poor prognosis; innovative treatment strategies are required to improve the current 5-year survival rate of 30-40%....
- 4From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedB-cell chronic lymphocytic leukemia (B-CLL) is a common hematological malignancy that typically follows an indolent course over many years. However, with longer disease course and recurring anti-B-CLL therapy, in...
- 5From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedSHIP-1 (SH2 (Src homology 2)-containing inositol 5'-phosphatase-1) functions as a negative regulator of immune responses by hydrolyzing phosphatidylinositol-3,4,5-triphosphate generated by phosphoinositide-3 (PI...
- 6From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedGalectins constitute a family of lectins that specifically exhibit the affinity for [beta]-galactosides and modulate various biological events. Galectin-9 is a tandem-repeat type galectin with two carbohydrate...
- 7From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedThe recently published study by Davies et al., (1) confirms previous data from our laboratory indicating that nilotinib, unlike imatinib, does not require the human organic cation transporter-1 (hOCT-1) for active...
- 8From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedIn chronic myelogenous leukemia (CML), hematopoietic stem cell transformation leads to increased proliferation of malignant myeloid progenitors. The cyclin-dependent kinase inhibitor p27kip1 (p27) is a critical negative...
- 9From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedAcute myeloid leukemia (AML) is characterized by the presence of recurrent chromosomal aberrations. One of these rearrangements, the inv(16), is present in approximately 10% of cases with AML. Patients with this...
- 10From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedImatinib (STI-571, Gleevec; Novartis, Basel, Switzerland) is an adenosine-5'-triphosphate (ATP)-competitive tyrosine kinase inhibitor that is highly effective in the treatment of chronic myeloid leukemia and...
- 11From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedWe read with interest the article by Cortelezzi et al. (1) published in a recent issue of this journal. They report their experience with low-dose subcutaneous alemtuzumab (10 mg three times per week for 18 weeks) in 49...
- 12From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedEarlier, we identified a nucleoside analog named ARC (4-amino-6-hydrazino-7-[beta]-D-ribofuranosyl-7H-pyrrolo[2,3-d]- pyrimidine-5-carboxamide), which is a CDK9/transcriptional inhibitor. (1) We and others showed that...
- 13From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedEssential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by a sustained increase in platelet count and long-term survival. The long-standing threshold platelet count to define thrombocytosis of 600...
- 14From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedChronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is characterized by the slow accumulation of small, mature B cells and prolymphocytes that typically display the CD5, CD19, CD23 and CD20 markers....
- 15From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedIn chronic myeloid leukemia (CML) cell lines, brief exposure to pharmacologically relevant dasatinib concentrations results in apoptosis. In this study, we assess the impact of intensity and duration of Bcr-Abl kinase...
- 16From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedAurora kinases are a family of protein kinases that have a key role in multiple stages of mitosis. Over-expression of Aurora kinases, particularly Aurora A, has been demonstrated in a number of solid tumors and...
- 17From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedRetinoic acid (RA) relieves the maturation block in t(15:17) acute promyelocytic leukemia (APL), leading to granulocytic differentiation. However, RA treatment alone invariably results in RA resistance, both in vivo and...
- 18From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedIn acute myeloid leukemia (AML), molecular analyses of chromosomal translocations have led to the discovery of gene rearrangements, which can result in block of differentiation and uncontrolled cellular growth. (1) One...
- 19From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedProtein tyrosine kinases are important regulators of intracellular signal-transduction pathways mediating cellular proliferation, survival and development. The activity of these kinases is normally tightly regulated,...
- 20From: Leukemia. (Vol. 24, Issue 4) Peer-ReviewedThe receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen in chronic lymphocytic leukemia (CLL). [CD8.sup.+] T cells primed with the RHAMM-derived epitope R3, which is restricted by human...